Extended indication Ryzneuta is indicated for the reduction in the duration of neutropenia and the incidence of febrile
Therapeutic value No estimate possible yet
Registration phase Registered

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information